The short answer
Liraglutide is a once-daily injectable GLP-1 receptor agonist. Saxenda is approved for chronic weight management in adults and children 12 and older who meet label criteria. Victoza is approved for type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and heart disease. Both carry a boxed warning about thyroid C-cell tumors.
Boxed warning: risk of thyroid C-cell tumors
Liraglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
Labels also warn about pancreatitis, gallbladder disease, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, and suicidal thoughts (Saxenda). It should not be used during pregnancy for weight loss.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Saxenda (liraglutide) | 2026-02-25 | Thyroid C-cell tumors |
| Victoza (liraglutide) | 2025-10-14 | Thyroid C-cell tumors |
Established evidence
Is Saxenda the same as Victoza?
They share an active ingredient but are separate products with different approved uses, pen strengths, and maximum doses. Saxenda is labeled for weight management; Victoza is labeled for type 2 diabetes. A pharmacist cannot simply substitute one for the other.
| Feature | Saxenda | Victoza |
|---|---|---|
| Approved use | Chronic weight management | Type 2 diabetes; cardiovascular risk reduction in type 2 diabetes with heart disease |
| Ages | Adults and children 12 and older meeting criteria | Adults and children 10 and older with type 2 diabetes |
| Dosing | Daily injection, titrated | Daily injection, titrated |
Established evidence
How it works
Liraglutide mimics the gut hormone GLP-1. It slows stomach emptying, increases fullness, and helps the pancreas release insulin when blood sugar is high. Its effect lasts about a day, so it is injected daily, unlike weekly semaglutide or tirzepatide.
Established evidence
What the evidence shows
In the SCALE trials, adults without diabetes taking Saxenda alongside lifestyle changes lost more weight on average than those on placebo, though average weight loss was smaller than later trials of semaglutide 2.4 mg and tirzepatide. Victoza's LEADER trial showed reduced major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. Cross-trial comparisons are imperfect because populations and designs differ.
Established evidence
Common side effects
- Nausea, vomiting, diarrhea, constipation
- Headache and fatigue
- Injection-site reactions
- Low blood sugar, especially with other diabetes medicines
- Increased heart rate
Why it matters in midlife
Many people notice weight gain and a shift toward abdominal fat around the menopause transition. GLP-1 medicines treat obesity and diabetes; they are not menopause treatments and do not treat hot flashes. Preserving muscle with adequate protein and strength training is especially important during midlife weight loss.
Questions to ask a healthcare professional
- Would a daily or weekly GLP-1 suit me better?
- Does my insurance cover Saxenda, generic liraglutide, or neither?
- How do we protect muscle and bone while losing weight?
Questions, answered
What people ask about Saxenda; Victoza
Is liraglutide the same as semaglutide?+
No. Both are GLP-1 receptor agonists, but they are different molecules. Liraglutide is injected daily; semaglutide is injected weekly or taken as a daily tablet depending on the product.
Is there a generic Saxenda or Victoza?+
The FDA has approved generic liraglutide products. Which strengths and indications are available varies, so check with a pharmacist.
Is liraglutide a menopause medication?+
No. It is approved for weight management or type 2 diabetes, not for menopause symptoms.
Does Kindr Health offer liraglutide?+
This page is educational and does not state or imply availability through Kindr Health.
Kindr Health does not claim to offer Saxenda; Victoza on this page. Availability and prescribing are not implied.
A broader care pathway
Explore metabolic health care
Learn how Kindr Health care pathways work. Any treatment decision is made by a licensed professional; a prescription is never guaranteed.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Saxenda prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Saxenda
- Victoza prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Victoza
- Prescription medications to treat overweight and obesity (2024) — NIH National Institute of Diabetes and Digestive and Kidney Diseases. www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.